[1]李振宁 杨巍.生物可降解镁合金支架的目前研究和展望[J].心血管病学进展,2021,(5):425-428.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.010]
　LI ZHenning,YANG Wei.Current Research and Prospects of Biodegradable Magnesium Alloy Stents[J].Advances in Cardiovascular Diseases,2021,(5):425-428.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.010]
点击复制

生物可降解镁合金支架的目前研究和展望()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年5期
页码:
425-428
栏目:
综述
出版日期:
2021-05-25

文章信息/Info

Title:
Current Research and Prospects of Biodegradable Magnesium Alloy Stents
作者:
李振宁1 杨巍 2
(1. 哈尔滨医科大学,黑龙江 哈尔滨 150000;2.哈尔滨医科大学附属第四医院心内科,黑龙江 哈尔滨 150000)
Author(s):
LI ZHenning; YANG Wei
(1. Harbin Medical UniversityHarbin 150000, Heilongjiang,China; 2. Department of Cardiology,The Fourth Affiliated Hospital of Harbin Medical University,Harbin 150000,Heilongjiang,China)
关键词:
可降解; 镁合金支架; 生物相容性; 新型支架
Keywords:
Biodegradable; Magnesium alloy stent;  Biocompatibility;  New stent
DOI:
10.16806/j.cnki.issn.1004-3934.2021.05.010
摘要:
1977年进行的经皮冠状动脉腔内成形术开启了冠心病介入治疗的新时代。随后经历了金属裸支架、药物洗脱支架和生物可降解支架。聚合物材料可降解支架因径向支撑力不足，降解产物对血管壁产生较持续的炎症等问题，并非完美。近年来发现可降解镁合金具有良好的生物相容性。基础试验和临床试验证实了其安全性和持久性。现论述可降解镁合金支架的优缺点，并展望以WE43镁合金为基础，三氧化二砷为药物涂层，实现药物靶向释放的新型支架。
Abstract:
In 1977,percutaneous transluminal coronary angioplasty (PTCA) opened a new era of interventional treatment for coronary heart disease. Then we went through bare metal stent,drug eluting stent and biodegradable stent.Polymer biodegradable stent is not perfect because of the lack of radial support and the continuous inflammation of the vascular wall caused by the degradation products.In recent years,it has been discovered that magnesium alloys have good biocompatibility. Basic tests and clinical trials have confirmed their safety and durability. This article review s the advantages and disadvantages of degradable magnesium alloy stent, and prospects a new stent based on WE43 magnesium alloy and arsenic trioxide as the drug coating to achieve targeted drug release

参考文献/References:



[1]Gruntzig A. Transluminal dilatation of coronary-artery stenosis[J].Lancet,1978,1(8058):263.

[2] Liang C, Hu Y, Wang H, et al. Biomimetic cardiovascular stents for in vivo re-endothelialization[J]. Biomaterials,2016,103:170-182.

[3]Colombo A, Karvouni E. Biodegradable stents:“fulfilling the mission and stepping away”[J]. Circulation,2000,102(4):371-373.

[4]韩欣宇,杨魏. 生物可降解镁合金支架研究现状和进展[J]. 医学综述,2015,21(6):981-983.

[5] Garg S,Serruys PW. Coronary stents:looking forward[J]. J Am Coll Cardiol,2010,56(10 suppl):S43-S78.

[6]陈华,赵仙先. 生物可降解镁合金支架研究现状[J]. 介入放射学杂志,2011,20(1):62-64.

[7]Saris NE,Mervaala E,Karppanen H,et al. Magnesium. An update on physiological,clinical and analytical aspects[J]. Clin Chim Acta,2000,294(1-2):1-26.

[8]肖健勇,刘寅. 镁合金可吸收金属支架的研究进展[J]. 天津医药,2011,39(3):285-287.

[9]Anisimova N,Kiselevskiy M,Martynenko N,et al. Cytotoxicity of biodegradable magnesium alloy WE43 to tumor cells in vitro:bioresorbable implants with antitumor activity?[J].J Biomed Mater Res B Appl Biomater,2020,108(1):167-173.

[10]赵辉,雷民. 新型可吸收镁合金支架在血管内应用及生物相容性[J]. 中国组织工程研究,2016,20(8):1165-1170.

[11]Fei J,Wen X,Lin X,et al. Biocompatibility and neurotoxicity of magnesium alloys potentially used for neural repairs[J].Mater Sci Eng C Mater Biol Appl,2017,78:1155-1163.

[12]Yahata C,Mochizuki A. Platelet compatibility of magnesium alloys[J].Mater Sci Eng C Mater Biol Appl,2017,78:1119-1124.

[13]Wang S,Zhang X,Li J,et al. Investigation of Mg-Zn-Y-Nd alloy for potential application of biodegradable esophageal stent material[J]. Bioact Mater,2020,5(1):1-8.

[14] Heublein B,Rohde R,Kaese V,et al. Biocorrosion of magnesium alloys:a new principle in cardiovascular implant technology? [J].Heart,2003,89(6):651-656.

[15]di Mario C,Griffiths H,Goktekin O,et al. Drug-eluting bioabsorbable magnesium stent[J].J Interv Cardiol,2004,17(6):391-395.

[16]Waksman R,Pakala R,Kuchulakanti PK,et al. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries[J].Catheter Cardiovasc Interv,2006,68(4):607-619.

[17]Zartner P,Cesnjevar R,Singer H,et al. First successful implantation of a biodegradable metal stent into the left pulmonary artery of a preterm baby[J]. Catheter Cardiovasc Interv,2005,66(4):590-594.

[18]Peeters P,Bosiers M,Verbist J,et al. Preliminary results after application of absorbable metal stents in patients with critical limb ischemia[J].J Endovasc Ther,2005,12(1):1-5.

[19]Zartner PA,Schranz D,Mini N,et al. Acute treatment of critical vascular stenoses with a bioabsorbable magnesium scaffold in infants with CHDs[J]. Cardiol Young,2020,30(4):493-499.

[20]Erbel R,di Mario C,Bartunek J,et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents:a prospective,non-randomised multicentre trial[J]. Lancet, 2007 ,369(9576):1869-1875.

[21]Haude M,Erbel R,Erne P,et al. Safety and performance of the DRug-Eluting Absorbable Metal Scaffold(DREAMS) in patients with de novo coronary lesions:3-year results of the prospective,multicentre,first-in-man BIOSOLVE-I trial[J].EuroIntervention,2016,12(2):e160-e166.

[22]Haude M,Ince H,Abizaid A,et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-Ⅱ):6 month results of a prospective,multicentre,non-randomised,first-in-man trial[J]. Lancet,2016,387(10013):31-39.

[23]Haude M,Ince H,Abizaid A,et al. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions:12-month clinical results and angiographic findings of the BIOSOLVE-Ⅱfirst-in-man trial[J].Eur Heart J,2016,37(35):2701-2709.

[24] Haude M,Ince H,Kische S,et al. Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries:pooled 12-month outcomes of BIOSOLVE-Ⅱand BIOSOLVE-Ⅲ[J]. Catheter Cardiovasc Interv,2018,92(7):E502-E511.

[25] Moravej M,Mantovani D. Biodegradable metals for cardiovascular stent application:interests and new opportunities[J].Int J Mol Sci,2011,12(7):4250-4270.

[26] Seitz JM,Durisin M,Goldman J,et al. Recent advances in biodegradable metals for medical sutures:a critical review[J].Adv Healthc Mater,2015,4(13):1915-1936.

[27]廖燚,王勇平,何耀华,等.可降解镁合金腐蚀及生物相容性[J].国际骨科学杂志,2011,32(3):158-160,169.

[28] Devito F,Zito A,Dachille A,et al. Bioresorbable vascular scaffolds:design,clinical trials,and current applications[J].Coron Artery Dis,2016,27(2):151-158.

[29] Ang HY,Bulluck H,Wong P,et al. Bioresorbable stents:current and upcoming bioresorbable technologies[J].Int J Cardiol,2017,228:931-939.

[30] Stanetic BM,Iqbal J,Onuma Y,et al. Novel bioresorbable scaffolds technologies:current status and future directions[J].Minerva Cardioangiol,2015,63(4):297-315.

[31] Wiebe J,Nef HM,Hamm CW. Current status of bioresorbable scaffolds in the treatment of coronary artery disease[J]. J Am Coll Cardiol,2014,64(23):2541-2551.

[32] Huang W,Zeng YC. A candidate for lung cancer treatment:arsenic trioxide[J]. Clin Transl Oncol,2019,21(9):1115-1126.

[33] Zhang L,Zhou Y,Kong J,et al. Effect of arsenic trioxide on cervical cancer and its mechanisms[J]. Exp Ther Med,2020,20(6):169.

[34] Yang W,Ge J, Liu H,et al. Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model[J]. Cardiovasc Res,2006,72(3):483-493.

[35] Zhao Y,Zang G,Yin T,et al. A novel mechanism of inhibiting in-stent restenosis with arsenic trioxide drug-eluting stent:enhancing contractile phenotype of vascular smooth muscle cells via YAP pathway[J]. Bioact Mater,2020,6(2):375-385.

[36] Zhao Y,Du R,Zhou T,et al. Arsenic trioxide-coated stent is an endothelium-friendly drug eluting stent[J]. Adv Healthc Mater,2018,7(15):e1800207.

[37] Zhang S,Zhang Y,Li S,et al. Efficacy of arsenic trioxide drug-eluting stents in the treatment of coronary heart disease[J]. Exp Ther Med,2017,13(4):1634-1636.

[38] Iqbal J,Gunn J,Serruys PW. Coronary stents:historical development,current status and future directions[J]. Br Med Bull,2013,106:193-211.

更新日期/Last Update: 2021-06-17